PAUL GEISE: Open Payments
NPI 1457895666 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,384 in 117 payments from 10 companies in 2025. Trend: 2023 $2,478 · 2024 $1,851 · 2025 $2,384
Food & beverage: $2,384
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $601 |
| Alkermes, Inc. | 14 | $380 |
| E.R. Squibb & Sons, L.L.C. | 20 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $284 |
| Otsuka America Pharmaceutical, Inc. | 8 | $228 |
| ABBVIE INC. | 10 | $158 |
| Lundbeck LLC | 6 | $111 |
| Neurocrine BioSciences, Inc. | 6 | $105 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
Products named: UZEDY, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, LYBALVI, VRAYLAR, ARISTADA, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
